Mesfin, Fikir M.Manohar, KrishnaShelley, W. ChristopherBrokaw, John P.Liu, JianyunMa, MinglinMarkel, Troy A.2024-08-262024-08-262023Mesfin FM, Manohar K, Shelley WC, et al. Stem cells as a therapeutic avenue for active and long-term complications of Necrotizing Enterocolitis. Semin Pediatr Surg. 2023;32(3):151311. doi:10.1016/j.sempedsurg.2023.151311https://hdl.handle.net/1805/42957Necrotizing enterocolitis (NEC) is a devastating neonatal intestinal disease associated with significant morbidity and mortality. Although decades of research have been dedicated to understanding the pathogenesis of NEC and developing therapies, it remains the leading cause of death among neonatal gastrointestinal diseases. Mesenchymal stem cells (MSCs) have garnered significant interest recently as potential therapeutic agents for the treatment of NEC. They have been shown to rescue intestinal injury and reduce the incidence and severity of NEC in various preclinical animal studies. MSCs and MSC-derived organoids and tissue engineered small intestine (TESI) have shown potential for the treatment of long-term sequela of NEC such as short bowel syndrome, neurodevelopmental delay, and chronic lung disease. Although the advances made in the use of MSCs are promising, further research is needed prior to the widespread use of these cells for the treatment of NEC.en-USPublisher PolicyBronchopulmonary dysplasiaIntestinal failureMesenchymal stem cellsNeurodevelopmental delayArticle